scholarly journals Prognostic factors for acute myeloid leukaemia in adults - biological significance and clinical use

2014 ◽  
Vol 165 (1) ◽  
pp. 17-38 ◽  
Author(s):  
Ruediger Liersch ◽  
Carsten Müller-Tidow ◽  
Wolfgang E. Berdel ◽  
Utz Krug
Keyword(s):  
Prognostic Factors ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Biological Significance ◽  
Clinical Use ◽  
Acute Myeloid

scholarly journals Favourable prognostic factors in therapy related acute myeloid leukaemia

2011 ◽  
Vol 139 (5-6) ◽  
pp. 347-352 ◽  
Author(s):  
Nebojsa Antonijevic ◽  
Nada Suvajdzic ◽  
Tatjana Terzic ◽  
Branko Jakovljevic ◽  
Gradimir Jankovic ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Radiation Treatment ◽  
World Health ◽  
Probability Of Survival ◽  
Impact On Survival ◽  
Cytogenetic Analyses ◽  
Health Organization ◽  
Acute Myeloid

Introduction. Therapy related acute myeloid leukaemia (t-AML) is a distinct clinical entity recognized by the World Health Organization classification occurring after chemotherapy and/or radiation treatment administered for a previous disease. T-AML is characterised by pancytopenia, three-lineage myelodysplasia, high frequency of unfavourable cytogenetics and short survival. Objective. The aim of this study was to analyse clinical, cytogenetic, and cytological characteristics of t-AML and their impact on survival. Methods. Seventeen patients with t-AML (8 male and 9 female; median age 59 years) were identified among 730 consecutive patients with acute myeloid leukaemia. The degree of three-lineage dysplasia as well as haematological, cytological and cytogenetic analyses, were assessed by standard methods. Results. The patients survived a median of 62.5 days with the 10% probability of survival during two years. Prognostically favourable factors were a higher percentage of dysplastic granulocytic cells, age less than 60 years, and presence of prognostically favourable karyotype inv(16), t(15;17), t(8;21). Conclusion. The stated prognostic factors that include age, cytogenetics findings and granulocytic dysplasia analysis could contribute to adequate risk stratification of t-AML, though fuller results would require additional analyses.

scholarly journals Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy

2014 ◽  
Vol 168 (1) ◽  
pp. 94-101 ◽  
Author(s):  
Seth E. Karol ◽  
Elaine Coustan-Smith ◽  
Xueyuan Cao ◽  
Sheila A. Shurtleff ◽  
Susana C. Raimondi ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Induction Therapy ◽  
Remission Induction ◽  
Excellent Response ◽  
Acute Myeloid

scholarly journals Combined analysis of differentiation inhibitory factor nm23-H1 and nm23-H2 as prognostic factors in acute myeloid leukaemia

1998 ◽  
Vol 77 (12) ◽  
pp. 2298-2303 ◽  
Author(s):  
N Wakimoto ◽  
A Yokoyama ◽  
J Okabe-Kado ◽  
N Nagata ◽  
K Motoyoshi ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Inhibitory Factor ◽  
Combined Analysis ◽  
Acute Myeloid

Acute Myeloid Leukaemia

2020 ◽  
pp. 124-133
Author(s):  
Gertjan Kaspers ◽  
Dirk Reinhardt
Keyword(s):  
Down Syndrome ◽  
Stem Cell ◽  
Prognostic Factors ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Residual Disease ◽  
Study Groups ◽  
Cooperative Study ◽  
Minimal Residual ◽  
Acute Myeloid

Acute myeloid leukaemia (AML) is the second most frequent type of leukaemia in children, and is cured nowadays in about 75% of patients in settings with essentially unlimited resources. This chapter discusses the aetiology and epidemiology of this interesting disease, its typical clinical presentation, diagnostics, and biology. The classifications, prognostic factors, and risk stratification (including minimal residual disease), and AML treatment (covering chemotherapy and allogeneic stem-cell transplantation) is presented. Several practical illustrations are included, and results of recent studies from the main cooperative study groups are summarized. Finally, side effects during treatment and late effects, as well as acute promyelocytic leukaemia (APL) and myeloid leukaemia of Down syndrome (ML-DS), are discussed. The chapter concludes with the actual challenges and perspectives.

Sign in / Sign up

Export Citation Format

Share Document